EXTRAOCULAR-MUSCLES IN GRAVES OPHTHALMOPATHY - USEFULNESS OF T2 RELAXATION-TIME MEASUREMENTS

被引:59
作者
OHNISHI, T [1 ]
NOGUCHI, S [1 ]
MAURAKAMI, N [1 ]
TAJIRI, J [1 ]
HARAO, M [1 ]
KAWAMOTO, H [1 ]
HOSHI, H [1 ]
JINNOUCHI, S [1 ]
FUTAMI, S [1 ]
NAGAMACHI, S [1 ]
WATANABE, K [1 ]
机构
[1] MIYAZAKI MED COLL,DEPT RADIOL,MIYAZAKI 88916,JAPAN
关键词
ORBIT; INFLAMMATION; 224.522; 2246.249; 2247.249; MR; 224.121411; THERAPEUTIC RADIOLOGY; 224.1293;
D O I
10.1148/radiology.190.3.8115640
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To determine if T2 relaxation time measurements with magnetic resonance (MR) imaging in patients with Graves ophthalmopathy (GO) can predict response to therapy. MATERIALS AND METHODS: Studied were 84 patients with GO, 27 with Graves disease without ophthalmopathy (GD), and 12 control subjects without Graves disease. T2 times of extraocular muscles and retrobulbar fat tissue were measured. Twenty-five patients with GO were treated with systemic corticosteroids and retroorbital radiation therapy. RESULTS: T2 relaxation times of muscles in patients with GD were the same as those in controls but were longer in patients with GO (P < .05). T2 times of fat in all patients were the same as those of the controls. The predicted probability of response to treatment increased with increased mean T2 relaxation times of extraocular muscles prior to therapy. Of the 25 patients with combined therapy, only those with particularly prolonged T2 relaxation times showed impressive response. CONCLUSIONS: T2 relaxation time measurements with MR allow noninvasive detection of acute muscle inflammation and predict which patients with GO will likely benefit from antiinflammatory therapy.
引用
收藏
页码:857 / 862
页数:6
相关论文
共 19 条
[1]   ORBITAL COBALT IRRADIATION COMBINED WITH SYSTEMIC CORTICOSTEROIDS FOR GRAVES OPHTHALMOPATHY - COMPARISON WITH SYSTEMIC CORTICOSTEROIDS ALONE [J].
BARTALENA, L ;
MARCOCCI, C ;
CHIOVATO, L ;
LADDAGA, M ;
LEPRI, G ;
ANDREANI, D ;
CAVALLACCI, G ;
BASCHIERI, L ;
PINCHERA, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (06) :1139-1144
[2]  
CHAR DH, 1990, THYROID EYE DIS, P35
[3]  
CONOVER WJ, 1980, PRACTICAL NONPARAMET, P256
[4]   SUPERVOLTAGE ORBITAL RADIOTHERAPY FOR GRAVES OPHTHALMOPATHY [J].
DONALDSON, SS ;
BAGSHAW, MA ;
KRISS, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1973, 37 (02) :276-285
[5]  
ENZMANN DR, 1979, J COMPUT ASSIST TOMO, V3, P815
[6]   THYROID-ASSOCIATED EYE DISEASE - CLINICAL MANAGEMENT [J].
FELLS, P .
LANCET, 1991, 338 (8758) :29-32
[7]  
Hosmer D.W., 1989, APPL LOGISTIC REGRES, P16
[8]   GRAVES OPHTHALMOPATHY - MR IMAGING OF THE ORBITS [J].
HOSTEN, N ;
SANDER, B ;
CORDES, M ;
SCHUBERT, CJ ;
SCHORNER, W ;
FELIX, R .
RADIOLOGY, 1989, 172 (03) :759-762
[9]   RADIATION-THERAPY FOR THYROID EYE DISEASES [J].
HURBLI, T ;
CHAR, DH ;
HARRIS, J ;
WEAVER, K ;
GREENSPAN, F ;
SHELINE, G .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1985, 99 (06) :633-637
[10]   TISSUE CHARACTERIZATION OF BENIGN BRAIN-TUMORS - USE OF NMR-TISSUE PARAMETERS [J].
JUST, M ;
HIGER, HP ;
SCHWARZ, M ;
BOHL, J ;
FRIES, G ;
PFANNENSTIEL, P ;
THELEN, M .
MAGNETIC RESONANCE IMAGING, 1988, 6 (04) :463-472